Kestra Advisory Services LLC acquired a new position in Haleon plc (NYSE:HLN – Get Rating) stock during the third quarter, pursuant to its recent 13F filing with the Securities and Exchange Commission. The fund acquired 70,453 shares of the company’s shares, valued at approximately $429,000.
→ The next big crisis is here (By Porter & Company)
A number of other hedge funds and other institutional investors recently changed their positions in the stock. Whittier Trust Co. of Nevada Inc. acquired a new position in Haleon stock valued at approximately $28,000 during the third quarter. Assetmark Inc. acquired a new position in Haleon stock valued at approximately $29,000 during the third quarter. Benjamin F. Edwards & Company Inc. acquired a new position in Haleon stock valued at approximately $33,000 during the third quarter. City Holding Co. acquired a new position in Haleon stock valued at approximately $34,000 during the third quarter. Finally, during the third quarter, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in Haleon stock valued at approximately $60,000. 6.67% of the shares are currently held by institutional investors.
Haleon trade up 0.6%
Haleon shares opened at $8.03 on Monday. The stock has a 50-day moving average price of $7.65. Haleon plc has a 52-week low of $5.59 and a 52-week high of $8.50.
Wall Street analysts forecast growth
Several brokers have recently issued reports on HLN. Morgan Stanley upgraded shares of Haleon from an “Equal Weight” rating to an “Overweight” rating in a research note on Friday, January 6th. Barclays upgraded shares of Haleon from an “Equal Weight” rating to an “Overweight” rating in a research note on Wednesday, December 7th. One equities research analyst has assigned a sell rating to the stock, four have given a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $298.00.
Haleon Company Profile
(received rating)
Haleon plc is engaged in the research and development, manufacture and sale of a variety of consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America and Asia Pacific. The Company offers therapeutic oral health, pain relief, respiratory health, digestive health and other products, as well as vitamins, minerals and nutritional supplements.
Featured Stories
Want to see what other hedge funds are holding HLN? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Haleon plc (NYSE:HLN – Get Rating).
This instant news alert was generated by MarketBeat’s narrative science technology and financial data to provide readers with the fastest, most accurate reporting. This story was reviewed by the MarketBeat editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider Haleon, here’s what you should hear.
MarketBeat tracks Wall Street’s best-in-class, top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now, before the broader market takes hold… and Haleon wasn’t on the list.
While Haleon is currently rated a Hold by analysts, top analysts believe these five stocks are better buys.
Check out the five stocks here
